Qiagen

Last updated

QIAGEN N.V.
Company type Public ( Naamloze vennootschap )
ISIN NL0015001WM6
Industry Biotechnology
FoundedNovember 29, 1984;39 years ago (1984-11-29)
Founders
  • Metin Colpan
  • Karsten Henco
  • Jürgen Schumacher
Headquarters
  • Venlo, Netherlands (corporate)
  • Hilden, Germany (operational)
Key people
  • Thierry Bernard (CEO)
  • Lawrence A. Rosen (chairman of supervisory board)
RevenueDecrease2.svg US$1.97 billion (2023)
Decrease2.svgUS$410 million (2023)
Decrease2.svgUS$341 million (2023)
Total assets Decrease2.svgUS$6.12 billion (2023)
Total equity Increase2.svgUS$3.81 billion (2023)
Number of employees
5,967 (2023)
Website qiagen.com
Footnotes /references
[1] [2]

QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. [3] European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. [4] QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer (CEO).

Contents

History

In 1984, QIAGEN was established on November 29 by a team of scientists at the Heinrich Heine University Düsseldorf, Germany. Two years later, QIAGEN launched its first product. A kit for the purification of plasmids—small ring-shaped DNA molecules in bacterial cells. [5] 1996 saw the initial public offering of QIAGEN on the technology-oriented Nasdaq stock exchange, becoming the first German company to do so. [6] 1997 saw the initial public offering on the Frankfurt Stock Exchange in Germany. [7]

Acquisitions

Qiagen Acquisitions
  • Qiagen
    • Molecular Staging, Inc. (Acq 2004)
    • Digene (Acq 2007)
    • Corbett Life Science (Acq 2008)
    • DxS Ltd (Acq 2009)
    • SABiosciences Corp. (Acq 2009)
    • ESE GmbH (Acq 2010)
    • Ipsogen S.A. (Acq 2011)
    • Cellestis Limited (Acq 2011)
    • Ingenuity Systems (Acq 2013)
    • CLC bio (Acq 2013)
    • Exiqon (Acq 2016)
    • STAT-Dx (Acq 2018)
    • Formulatrix (Acq 2019)
    • OmicSoft (Acq 2017)
    • N-of-One (Acq 2019)
    • Molecular Staging, Inc. (Acq 2020)
    • NeuMoDx Molecular Inc (Acq 2020)
    • Verogen (Acq 2023)

2020 Thermo Fisher Acquisition Target

On March 3, 2020, Thermo Fisher Scientific announced plans for the acquisition of QIAGEN at €39 per share in cash, which valued the transaction at $11.5 billion at the time. [8]

The day after an open letter by hedge fund Davidson Kempner Capital Management, one of QIAGEN's largest shareholders, to reject the bid as undervalued, [9] Thermo Fisher raised their tender by 10% to €43 per share, an advance of $1B in value. [10] Davidson Kempner subsequently increased their holdings from 5.1% to 7.3% of QIAGEN. [11]

The acquisition offer was terminated on August 13, 2020, having only reached the threshold of 47% shareholder approval, below the minimum 66.6% required as per the agreement. Davidson Kempner was notable for having continued to reject the bid. Because of the lapsed offer, QIAGEN was required to reimburse $95 Million to Thermo Fisher in expenses. [12]

On August 21, the chairman of the company's supervisory board, Håkan Björklund, stepped down to be immediately replaced by Lawrence Rosen. [13]

Resulting from the failed takeover bid, QIAGEN announced it would buy the outstanding 80.1% of shares in NeuMoDx Molecular Inc., which it did not already own, for about $234 million. [14]

Related Research Articles

<span class="mw-page-title-main">Merck Group</span> German multinational science and technology company

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name. The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

Zimmer Biomet Holdings, Inc. is a publicly traded medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

A special purpose acquisition company, also known as a "blank check company", is a shell corporation listed on a stock exchange with the purpose of acquiring a private company, thus making the private company public without going through the initial public offering process, which often carries significant procedural and regulatory burdens. According to the U.S. Securities and Exchange Commission (SEC), SPACs are created specifically to pool funds to finance a future merger or acquisition opportunity within a set timeframe; these opportunities usually have yet to be identified while raising funds.

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California, and it serves more than 155 countries. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

<span class="mw-page-title-main">Peer M. Schatz</span>

Peer M. Schatz is a Swiss and Austrian entrepreneur and executive in the life sciences. Among other roles, he was the chief executive officer of QIAGEN N.V. where he over almost 30 years led QIAGEN's development from a startup to a global market and technology leader with over 5100 employees and to a market capitalization of over $10 billion.

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American healthcare company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories. Before a merger with National Health Laboratory in 1995, the company operated under the name Roche BioMedical. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina, where the company is headquartered. As of 2018, Labcorp processes 2.5 million lab tests weekly.

<span class="mw-page-title-main">Patheon</span>

Patheon is a service brand within Thermo Fisher Scientific’s brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

<span class="mw-page-title-main">Elanco</span> American livestock and pet healthcare company

Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Davidson Kempner Capital Management</span> Global institutional alternative investment management firm

Davidson Kempner Capital Management LP is a global institutional alternative investment management firm with over $36 billion in assets under management. Davidson Kempner is headquartered in New York City, with additional offices in London, Hong Kong, Dublin, Philadelphia, Shenzhen and Mumbai. The firm is led by Anthony A. Yoseloff who serves as Executive Managing Member and Chief Investment Officer.

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

References

  1. "2023 Annual Report (Form 20-F)". US Securities and Exchange Commission. 11 March 2024.
  2. "Supervisory Board". Archived from the original on 11 July 2017.
  3. "Our global presence | QIAGEN". www.qiagen.com (in German). Retrieved 22 February 2024.
  4. "Company Presentation" (PDF). corporate.qiagen.com. 20 February 2024. Retrieved 20 February 2024.
  5. "Historical Development | QIAGEN". www.qiagen.com (in German). Retrieved 22 February 2024.
  6. Peter A. Brooke, Daniel Penrice (10 November 2009). A Vision for Venture Capital: Realizing the Promise of Global Venture Capital and Private Equity (Winthrop Group). ISBN   978-1584657996.
  7. "Historical Development | QIAGEN". www.qiagen.com (in German). Retrieved 22 February 2024.
  8. Terry, Mark (3 March 2020). "Thermo Fisher Expands Diagnostics Capabilities with $11.5 Billion Takeover of Qiagen". BioSpace.com. Retrieved 22 August 2020.
  9. "Davidson Kempner Letter to Qiagen NV". PRNewswire.Com (Press release). PRNewswire. Retrieved 22 August 2020.
  10. Keown, Alex (17 July 2020). "Thermo Fisher Ups QIAGEN Bid by $1 Billion". BioSpace.com. Retrieved 22 August 2020.
  11. Burger, Ludwig (31 July 2020). "Davidson Kempner ups stake in Qiagen to 7.3%". Reuters.com. Retrieved 22 August 2020.
  12. Slabodkin, Greg; Rachal, Maria; Paul Taylor, Nick (13 August 2020). "Thermo Fisher-Qiagen deal falls apart after failing to secure shareholder support". MedTechDive.com. Retrieved 22 August 2020.
  13. "QIAGEN announces new Chairman of Supervisory Board". Qiagen.com. 21 August 2020. Retrieved 22 August 2020.
  14. "Thermo Fisher's Qiagen bid fails after target gets COVID testing boost". Reuters. 13 August 2020.